Friedmann T, Roblin R. Gene therapy for human genetic disease? Science. 1972;175:949–55.
Google Scholar
Blaese RM, Culver KW, Miller AD, Carter CS, Fleisher T, Clerici M, et al. T lymphocyte-directed gene therapy for ADA- SCID: initial trial results after 4 years. Science. 1995;270:475–80.
Google Scholar
Tamura R, Toda M. Historic overview of genetic engineering technologies for human gene therapy. Neurol Med Chir. 2020;60:483–91.
Hacein-Bey-Abina S, von Kalle C, Schmidt M, Le Deist F, Wulffraat N, McIntyre E, et al. A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. N. Engl J Med. 2003;348:255–6.
Google Scholar
Dunbar CE, High KA, Joung JK, Kohn DB, Ozawa K, Sadelain, M. Gene therapy comes of age. Science. 2018;359.
Scheller EL, Krebsbach PH. Gene therapy: design and prospects for craniofacial regeneration. J Dent Res. 2009;88:585–96.
Google Scholar
Athanasopoulos T, Munye MM, Yáñez-Muñoz RJ. Nonintegrating gene therapy vectors. Hematol Oncol Clin North Am. 2017;31:753–70.
Google Scholar
Nienhuis AW, Dunbar CE, Sorrentino BP. Genotoxicity of retroviral integration in hematopoietic cells. Mol Ther. 2006;13:1031–49.
Google Scholar
Kessler PD, Podsakoff GM, Chen X, McQuiston SA, Colosi PC, Matelis LA, et al. Gene delivery to skeletal muscle results in sustained expression and systemic delivery of a therapeutic protein. Proc Natl Acad Sci USA. 1996;93:14082–7.
Google Scholar
Xiao X, Li J, Samulski RJ. Efficient long-term gene transfer into muscle tissue of immunocompetent mice by adeno-associated virus vector. J Virol. 1996;70:8098–108.
Google Scholar
Naso MF, Tomkowicz B, Perry WL 3rd, Strohl WR. Adeno-associated virus (AAV) as a vector for gene therapy. BioDrugs. 2017;31:317–34.
Google Scholar
Kotin RM, Siniscalco M, Samulski RJ, Zhu XD, Hunter L, Laughlin CA, et al. Site-specific integration by adeno-associated virus. Proc Natl Acad Sci USA. 1990;87:2211–5.
Google Scholar
Carter B, Burstein H, Peluso R. Adeno-associated virus and AAV vectors for gene delivery. Gene Therapy. CRC Press; Boca Raton, FL; 2003, pp. 71–101.
Pillay S, Zou W, Cheng F, Puschnik AS, Meyer NL, Ganaie SS, et al. Adeno-associated virus (AAV) serotypes have distinctive interactions with domains of the cellular AAV receptor. J Virol. 2017;91. https://doi.org/10.1128/JVI.00391-17.
Bessis N, GarciaCozar FJ, Boissier M-C. Immune responses to gene therapy vectors: influence on vector function and effector mechanisms. Gene Ther. 2004;11:S10–7.
Google Scholar
Rodrigues GA, Shalaev E, Karami TK, Cunningham J, Slater NKH, Rivers HM. Pharmaceutical development of AAV-based gene therapy products for the eye. Pharm Res. 2018;36:29.
Google Scholar
Bainbridge JWB, Smith AJ, Barker SS, Robbie S, Henderson R, Balaggan K, et al. Effect of gene therapy on visual function in Leber’s congenital amaurosis. N. Engl J Med. 2008;358:2231–9.
Google Scholar
Maguire AM, Simonelli F, Pierce EA, Pugh EN Jr, Mingozzi F, Bennicelli J, et al. Safety and efficacy of gene transfer for Leber’s congenital amaurosis. N. Engl J Med. 2008;358:2240–8.
Google Scholar
Hauswirth WW, Aleman TS, Kaushal S, Cideciyan AV, Schwartz SB, Wang L, et al. Treatment of Leber congenital amaurosis due to RPE65Mutations by ocular subretinal injection of adeno-associated virus gene vector: Short-term results of a phase I trial. Hum Gene Ther. 2008;19:979–90.
Google Scholar
Chacon-Camacho OF, Zenteno JC. Review and update on the molecular basis of Leber congenital amaurosis. World J Clin Cases. 2015;3:112–24.
Google Scholar
Pennesi ME, Stover NB, Stone EM, Chiang P-W, Weleber RG. Residual electroretinograms in young Leber congenital amaurosis patients with mutations of AIPL1. Investig Ophthalmol Vis Sci. 2011;52:8166–73.
Gao J, Hussain RM, Weng CY. Voretigene neparvovec in retinal diseases: A review of the current clinical evidence. Clin Ophthalmol. 2020;14:3855–69.
Google Scholar
Jacobson SG, Cideciyan AV, Ratnakaram R, Heon E, Schwartz SB, Roman AJ, et al. Gene therapy for leber congenital amaurosis caused by RPE65 mutations: safety and efficacy in 15 children and adults followed up to 3 years: Safety and efficacy in 15 children and adults followed up to 3 years. Arch Ophthalmol. 2012;130:9–24.
Google Scholar
Weleber RG, Pennesi ME, Wilson DJ, Kaushal S, Erker LR, Jensen L, McBride MT, et al. Results at 2 years after gene therapy for RPE65-deficient Leber congenital amaurosis and severe early-childhood-onset retinal dystrophy. Ophthalmology. 2016;123:1606–20.
Google Scholar
Chung DC, McCague S, Yu Z-F, Thill S, DiStefano-Pappas J, Bennett J, Cross D, et al. Novel mobility test to assess functional vision in patients with inherited retinal dystrophies. Clin Exp Ophthalmol. 2018;46:247–59.
Google Scholar
Bennett J, Wellman J, Marshall KA, McCague S, Ashtari M, DiStefano-Pappas J, et al. Safety and durability of effect of contralateral-eye administration of AAV2 gene therapy in patients with childhood-onset blindness caused by RPE65 mutations: a follow-on phase 1 trial. Lancet. 2016;388:661–72.
Google Scholar
Bainbridge JWB, Mehat MS, Sundaram V, Robbie SJ, Barker SE, Ripamonti C, et al. Long-term effect of gene therapy on Leber’s congenital amaurosis. N. Engl J Med. 2015;372:1887–97.
Google Scholar
Russell S, Bennett J, Wellman JA, Chung DC, Yu Z-F, Tillman A, et al. Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial. Lancet. 2017;390:849–60.
Google Scholar
Grishanin R, Vuillemenot B, Sharma P, Keravala A, Greengard J, Gelfman C, et al. Preclinical evaluation of ADVM-022, a novel gene therapy approach to treating wet age-related macular degeneration. Mol Ther. 2019;27:118–29.
Google Scholar
Kiss S, Oresic Bender K, Grishanin RN, Hanna KM, Nieves JD, Sharma P, et al. Long-term safety evaluation of continuous intraocular delivery of aflibercept by the intravitreal gene therapy candidate ADVM-022 in nonhuman primates. Transl Vis Sci Technol. 2021;10:34.
Google Scholar
Gelfman CM, Grishanin R, Bender KO, Nguyen A, Greengard J, Sharma P, et al. Comprehensive preclinical assessment of ADVM-022, an intravitreal anti-VEGF gene therapy for the treatment of neovascular AMD and diabetic macular edema. J Ocul Pharm Ther. 2021;37:181–90.
Kiss S, Roller CH, Turpcu A, Chung C, Osborne A. ADVM-022 Intravitreal Gene Therapy for Neovascular AMD—Results from the Phase 1 OPTIC Study, Presented at the American Society of Gene and Cellular Therapy (ASGCT) 24th Annual Meeting. 2021.
Khanani AM, Kiss S, Turpcu A, Hoang C, Osborne A; Phase 1 Study of Intravitreal Gene Therapy ADVM-022 for neovascular AMD (OPTIC Trial). Invest. Ophthalmol. Vis. Sci. 2020;61:1154.
Busbee BG, Boyer DS, Khanani AM, et al; Phase 1 Study of Intravitreal Gene Therapy with ADVM-022 for neovascular AMD (OPTIC Trial). Invest. Ophthalmol. Vis. Sci. 2021;62:352.
Kiss S, Grishanin R, Nguyen A, Rosario R, Greengard JS, Nieves J, et al. Analysis of aflibercept expression in NHPs following intravitreal administration of ADVM-022, a potential gene therapy for nAMD. Mol Ther Methods Clin Dev. 2020;18:345–53.
Google Scholar
Biotechnologies A. Adverum Provides Update on ADVM-022 and the INFINITY Trial in Patients with Diabetic Macular Edema. 2021.
Siddiqui FA, Aziz AA, Khanani AM. Gene Therapy for Neovascular AMD An update on ongoing clinical trials. Retinal Physician. 2020.
REGENXBIO Announces Additional Positive Interim Phase I/IIa and Long-Term Follow-Up Data of RGX-314 for the Treatment of Wet AMD. Prnewswire.com. Accessed 1 Apr 2021. http://www.prnewswire.com/news-releases/regenxbio-announces-additional-positive-interim-phase-iiia-and-long-term-follow-up-data-of-rgx-314-for-the-treatment-of-wet-amd-301228344.html.
Bahadorani S, Singer M. Recent advances in the management and understanding of macular degeneration. F1000Res. 2017;6:519.
Google Scholar
Nozaki M, Raisler BJ, Sakurai E, Sarma JV, Barnum SR, Lambris JD, et al. Drusen complement components C3a and C5a promote choroidal neovascularization. Am J Ophthalmol. 2006;142:201.
Dreismann AK, McClements ME, Barnard AR, Orhan E, Hughes JP, Lachmann PJ, et al. Functional expression of complement factor I following AAV-mediated gene delivery in the retina of mice and human cells. Gene Ther. 2021;28:265–76.
Google Scholar
Waheed NK. FOCUS Interim Results: GT005 Gene Therapy Phase I/II Study for the Treatment of Geographic Atrophy. Presented virtually at Angiogenesis, Exudation, and Degeneration 2021. 2021 Feb 12.
Tan LX, Toops KA, Lakkaraju A. Protective responses to sublytic complement in the retinal pigment epithelium. Proc Natl Acad Sci USA. 2016;113:8789–94.
Google Scholar
AAVCAGsCD59 for the Treatment of Wet AMD. Clinicaltrials.gov, Accessed 16 Aug 2021. https://clinicaltrials.gov/ct2/show/NCT03585556.
Treatment of Advanced Dry Age Related Macular Degeneration With AAVCAGsCD59. Clinicaltrials.gov. Accessed 20 Aug 2021. https://clinicaltrials.gov/ct2/show/NCT03144999?term=NCT03144999&rank=1
Duker JS. Update on Gene Therapy for Complement Inhibition: 1 Year Results of a Phase 1 Study. Presented at Angiogenesis, Exudation, and Degeneration 2019, Miami, FL. 2019 Feb 9.
Peng Y, Tang L, Zhou Y. Subretinal injection: A review on the novel route of therapeutic delivery for vitreoretinal diseases. Ophthalmic Res. 2017;58:217–26.
Google Scholar
Yiu G, Chung SH, Mollhoff IN, Nguyen UT, Thomasy SM, Yoo J, et al. Suprachoroidal and subretinal injections of AAV using transscleral microneedles for retinal gene delivery in nonhuman primates. Mol Ther Methods Clin Dev. 2020;16:179–91.
Google Scholar
de Smet MD, Lynch JL, Dejneka NS, Keane M, Khan IJ. A subretinal cell delivery method via suprachoroidal access in minipigs: Safety and surgical outcomes. Investig Ophthalmol Vis Sci. 2018;59:311–20.
Moisseiev E, Loewenstein A, Yiu G. The suprachoroidal space: from potential space to a space with potential. Clin Ophthalmol. 2016;10:173–8.
Google Scholar
Willoughby AS, Vuong VS, Cunefare D, Farsiu S, Noronha G, Danis RP, et al. Choroidal changes after Suprachoroidal Injection of Triamcinolone Acetonide in eyes with macular edema secondary to Retinal Vein Occlusion. Am J Ophthalmol. 2018;186:144–51.
Google Scholar
Emami-Naeini P, Yiu G. Medical and surgical applications for the suprachoroidal space. Int Ophthalmol Clin. 2019;59:195–207.
Google Scholar
Yiu G, Pecen P, Sarin N, Chiu SJ, Farsiu S, Mruthyunjaya P, et al. Characterization of the choroid-scleral junction and suprachoroidal layer in healthy individuals on enhanced-depth imaging optical coherence tomography. JAMA Ophthalmol. 2014;132:174–81.
Google Scholar
Ding K, Shen J, Hafiz Z, Hackett SF, Lima E, Silva R, Khan M, et al. AAV8-vectored suprachoroidal gene transfer produces widespread ocular transgene expression. J Clin Investig. 2019;129:4901–11.
Google Scholar
Shen J, Kim J, Tzeng SY, Ding K, Hafiz Z, Long D, et al. Suprachoroidal gene transfer with nonviral nanoparticles. Sci Adv. 2020;6. https://doi.org/10.1126/sciadv.aba1606.
Chung SH, Mollhoff IN, Mishra A, Sin T-N, Ngo T, Ciulla T, et al. Host immune responses after suprachoroidal delivery of AAV8 in nonhuman primate eyes. Hum Gene Ther. 2021;32:682–93.
Google Scholar
Mehta N, Robbins DA, Yiu G. Ocular inflammation and treatment emergent adverse events in retinal gene therapy. Int Ophthalmol Clin. 2021;61:151–77.
Google Scholar
Zaiss A-K, Liu Q, Bowen GP, Wong NCW, Bartlett JS, Muruve DA. Differential activation of innate immune responses by adenovirus and adeno-associated virus vectors. J Virol. 2002;76:4580–90.
Google Scholar
Vandamme C, Adjali O, Mingozzi F. Unraveling the complex story of immune responses to AAV vectors trial after trial. Hum Gene Ther. 2017;28:1061–74.
Google Scholar
Khabou H, Cordeau C, Pacot L, Fisson S, Dalkara D. Dosage thresholds and influence of transgene cassette in adeno-associated virus-related toxicity. Hum Gene Ther. 2018;29:1235–41.
Google Scholar
Mendell JR, Campbell K, Rodino-Klapac L, Sahenk Z, Shilling C, Lewis S, et al. Dystrophin immunity in Duchenne’s muscular dystrophy. N. Engl J Med. 2010;363:1429–37.
Google Scholar
Xiong W, Wu DM, Xue Y, Wang SK, Chung MJ, Rana P, et al. AAV cis-regulatory sequences are correlated with ocular toxicity. Proc Natl Acad Sci USA. 2019;116:5785–94.
Google Scholar
Heier JS, Kherani S, Desai S, Dugel P, Kaushal S, Cheng SH, et al. Intravitreous injection of AAV2-sFLT01 in patients with advanced neovascular age-related macular degeneration: a phase 1, open-label trial. Lancet. 2017;390:50–61.
Google Scholar
Maguire AM, Russell S, Wellman JA, Chung DC, Yu Z-F, Tillman A, et al. Efficacy, safety, and durability of voretigene neparvovec-rzyl in RPE65 mutation-associated inherited retinal dystrophy: Results of phase 1 and 3 trials. Ophthalmology. 2019;126:1273–85.
Google Scholar
Xue K, Jolly JK, Barnard AR, Rudenko A, Salvetti AP, Patrício MI, et al. Beneficial effects on vision in patients undergoing retinal gene therapy for choroideremia. Nat Med. 2018;24:1507–12.
Google Scholar
Seitz IP, Michalakis S, Wilhelm B, Reichel FF, Ochakovski GA, Zrenner E, et al. Superior retinal gene transfer and biodistribution profile of subretinal versus intravitreal delivery of AAV8 in nonhuman primates. Investig Ophthalmol Vis Sci. 2017;58:5792–801.
Yiu G. Genome editing in retinal diseases using CRISPR technology. Ophthalmol Retin. 2018;2:1–3.
Komor AC, Kim YB, Packer MS, Zuris JA, Liu DR. Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage. Nature. 2016;533:420–4.
Google Scholar
Gaudelli NM, Komor AC, Rees HA, Packer MS, Badran AH, Bryson DI, et al. Programmable base editing of A•T to G•C in genomic DNA without DNA cleavage. Nature. 2017;551:464–71.
Google Scholar
Anzalone AV, Randolph PB, Davis JR, Sousa AA, Koblan LW, Levy JM, et al. Search-and-replace genome editing without double-strand breaks or donor DNA. Nature. 2019;576:149–57.
Google Scholar
Latella MC, Di Salvo MT, Cocchiarella F, Benati D, Grisendi G, Comitato A, et al. In vivo editing of the human mutant Rhodopsin gene by electroporation of Plasmid-based CRISPR/Cas9 in the mouse retina. Mol Ther Nucleic Acids. 2016;5:e389.
Google Scholar
Tsai Y-T, Wu W-H, Lee T-T, Wu W-P, Xu CL, Park KS, et al. Clustered regularly interspaced short palindromic repeats-based genome surgery for the treatment of autosomal dominant retinitis pigmentosa. Ophthalmology. 2018;125:1421–30.
Google Scholar
Hollander AI, Koenekoop RK, Yzer S, Lopez I, Arends ML, Voesenek KEJ, et al. Mutations in the CEP290 (NPHP6) gene are a frequent cause of Leber congenital. Am J Hum Gen. 2006;79:556–61.
Ruan G-X, Barry E, Yu D, Lukason M, Cheng SH, Scaria A. CRISPR/Cas9-mediated genome editing as a therapeutic approach for Leber congenital amaurosis 10. Mol Ther. 2017;25:331–41.
Google Scholar
Yiu G, Tieu E, Nguyen AT, Wong B, Smit-McBride Z. Genomic disruption of VEGF-A expression in human retinal pigment epithelial cells using CRISPR-Cas9 endonuclease. Investig Ophthalmol Vis Sci. 2016;57:5490–7.
Chung SH, Mollhoff IN, Nguyen U, Nguyen A, Stucka N, Tieu E, et al. Factors impacting efficacy of AAV-mediated CRISPR-based genome editing for treatment of choroidal neovascularization. Mol Ther Methods Clin Dev. 2020;17:409–17.
Google Scholar
Keeler AM, Flotte TR. Recombinant adeno-associated virus gene therapy in light of luxturna (and zolgensma and glybera): Where are we, and how did we get here. Annu Rev Virol. 2019;6:601–21.
Google Scholar
